The purpose of this study is to examine if an internet-based exposure therapy is more effective in reducing excessive worry amongst patients who suffer from this problem than is internet-based stress management training.
Trial Objectives: Primary objective is to investigate whether an Internet-based exposure therapy can reduce the degree of excessive worry to a significantly greater extent than Internet-based stress-management training. The secondary objective is to a) investigate the cost-effectiveness of this treatment b) to study if any variables could moderate/mediate the treatment outcome, c) and to investigate the importance of sudden gains for the treatment outcome Trial Design: Randomized controlled trial with an active control and a waitlist control, who also will recieve treatment after the first group has finished. Duration: Ten weeks Primary Endpoint: Difference in worry symptoms between the treatment groups at week 10. Long term follow-up is also investigated (baseline to 4-months after treatment completion and baseline to 12-months after treatment completion). Efficacy Parameters: Penn State Worry Questionnaire (PSWQ) Safety Parameters: Adverse Events is assessed via the internet. Description of Trial Subjects: Patients \> 18 years old with a PSWQ score more than 56 points Number of Subjects: 300
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
311
The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book "Sluta älta och grubbla med kognitiv beteendeterapi" (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images.
The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
Karolinska Intitutet
Stockholm, Sweden
Penn State Worry Questionnaire (PSWQ)
Change in worry from baseline to Week 10 and at 4- and 12 months after treatment has ended.
Time frame: week 0, week 10 (weekly measurements), at 4 months follow up, 12 months follow up.
Montgomery Åsberg Depression Rating Scale (MADRS-S)
Change in depression from baseline to Week 10 and at 4- and 12 months after treatment has ended.
Time frame: Week 0, Week 10, 4 and 12 months follow-up
Euroqol, EQ-5D
Change in general health from baseline to Week 10 and at 4- and 12 months after treatment has ended
Time frame: Week 0, Week 10, 4 and 12 months follow-up
Cognitive Avoidance Questionnaire (CAQ)
Change in cognitive avoidance from baseline to Week 10, at 4- and 12 after treatment has ended, and weekly during treatment
Time frame: Week 0, Week 10, at 4 and 12 months follow up and weekly during treatment
Intolerance of uncertainty scale
Change in thought control efforts from baseline to Week 10, at 4- and 12 months after treatment has ended, and weekly during treatment
Time frame: Week 0, Week 10, at 4 and 12 months follow-up, and weekly during treatment
Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry (TIC-P)
Change in economic costs from baseline to Week 10 and at 4- and 12 months after treatment has ended
Time frame: Week 0, Week 10, 4 and 12 months follow-up
Brunnsviken Quality of Life Questionnaire (BBQ)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in self-perceived quality of life from baseline to week 10 and at 4 and 12 months after treatment has ended
Time frame: Week 0, Week 10, 4 and 12 months follow-up
Thought supression subscale of the Cognitive Avoidance Questionnaire (CAQ)
Weekly change in thought supression from baseline to Week 10
Time frame: Week 0 - Week 10 (weekly measurements)
The self-regulation subscale of the Multidimensional Assessment of Interoceptive Awareness
Weekly change in self-regulation from baseline to Week 10
Time frame: Week 0 - Week 10 (weekly measurements)
Patient Health Questionnaire-2
Weekly change in depressive symptom from baseline to Week 10
Time frame: Week 0 - Week 10 (weekly measurements)
Adverse Events
Number of adverse events from baseline to Week 10 and at 4 and 12 months
Time frame: Week 3, week 8, week 10, 4 and 12 months follow-up